FDA Approves Merck’s RECARBRIO™ for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

  06 June 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacaeEscherichia coliHaemophilus influenzaeKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniaePseudomonas aeruginosa and Serratia marcescens

Further reading: Business Wire
Author(s): Business Wire
Healthy Animals   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

More information

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed